Free Trial
→ The chokepoint supplier behind SpaceX's $1.75 trillion empire (From Behind the Markets) (Ad)tc pixel Free BLTE Stock Alerts

Belite Bio (BLTE) Financials

Belite Bio logo
$142.52 -0.48 (-0.34%)
As of 02:35 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare
Annual Income Statements for Belite Bio

Annual Income Statements for Belite Bio

This table shows Belite Bio's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -5.75 -9.67 -13 -32 -36 -78
Consolidated Net Income / (Loss)		 -5.75 -9.67 -13 -32 -36 -78
Net Income / (Loss) Continuing Operations		 -5.75 -9.67 -13 -32 -36 -78
Total Pre-Tax Income 		-5.75 -9.67 -13 -32 -36 -78
Total Operating Income		 -5.74 -9.80 -13 -32 -40 -84
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 5.74 9.80 13 32 40 84
Selling, General & Admin Expense		 2.06 2.38 3.95 6.82 10 39
Research & Development Expense		 3.69 7.42 8.87 25 30 45
Total Other Income / (Expense), net		 -0.01 0.13 0.17 0.05 3.86 6.60
Interest Expense		 0.02 0.00 0.02 0.03 0.02 0.00
Interest & Investment Income		 0.01 0.01 0.02 0.07 3.74 6.64
Other Income / (Expense), net		 0.00 0.13 0.17 -0.00 0.14 -0.04
Income Tax Expense		 0.00 0.00 0.00 0.01 0.01 0.00
Basic Earnings per Share		 ($0.65) ($1.01) ($0.63) ($1.19) ($1.18) ($2.31)
Weighted Average Basic Shares Outstanding		 8.79M 9.57M 19.98M 26.59M 30.54M 33.54M
Diluted Earnings per Share		 ($0.65) ($1.01) ($0.63) ($1.19) ($1.18) ($2.31)
Weighted Average Diluted Shares Outstanding		 8.79M 9.57M 19.98M 26.59M 30.54M 33.54M
Weighted Average Basic & Diluted Shares Outstanding		 - - 24.90M 29.15M 31.83M 39.34M

Quarterly Income Statements for Belite Bio

No quarterly income statements for Belite Bio are available.

Annual Cash Flow Statements for Belite Bio

This table details how cash moves in and out of Belite Bio's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 24 -8.27 25 46 -56 321
Net Cash From Operating Activities		 -4.44 -7.47 -11 -30 -29 -37
Net Cash From Continuing Operating Activities		 -4.44 -7.47 -11 -30 -29 -37
Net Income / (Loss) Continuing Operations		 -5.75 -9.67 -13 -32 -36 -78
Consolidated Net Income / (Loss)		 -5.75 -9.67 -13 -32 -36 -78
Depreciation Expense		 0.02 0.03 0.06 0.14 0.16 0.17
Amortization Expense		 0.00 0.00 0.13 0.00 0.00 0.01
Non-Cash Adjustments To Reconcile Net Income		 1.35 1.57 1.48 3.84 5.32 38
Changes in Operating Assets and Liabilities, net		 -0.05 0.60 -0.42 -2.18 1.43 2.86
Net Cash From Investing Activities		 -0.02 -0.06 -0.39 -0.06 -111 -305
Net Cash From Continuing Investing Activities		 -0.02 -0.06 -0.39 -0.06 -111 -305
Purchase of Property, Plant & Equipment		 0.00 -0.07 -0.39 -0.06 -0.12 -0.07
Acquisitions		 - - 0.00 0.00 -0.04 0.00
Purchase of Investments		 - - 0.00 0.00 -188 -452
Sale and/or Maturity of Investments		 - - 0.00 0.00 78 147
Other Investing Activities, net		 -0.02 - - 0.00 0.00 -0.11
Net Cash From Financing Activities		 28 -0.58 37 76 84 663
Net Cash From Continuing Financing Activities		 28 -0.58 37 76 84 663
Repurchase of Common Equity		 0.00 -0.82 -1.03 -1.23 -0.37 -7.98
Issuance of Common Equity		 0.50 0.00 38 55 16 154
Other Financing Activities, net		 0.09 0.23 0.00 22 67 517
Cash Interest Paid		 0.02 0.00 0.02 0.00 0.00 0.00
Cash Income Taxes Paid		 - 0.00 0.00 0.01 0.01 0.00

Quarterly Cash Flow Statements for Belite Bio

No quarterly cash flow statements for Belite Bio are available.

Annual Balance Sheets for Belite Bio

This table presents Belite Bio's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2021 2022 2023 2024 2025
Period end date 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 18 44 95 152 781
Total Current Assets		 17 43 90 147 494
Cash & Equivalents		 17 42 88 32 353
Short-Term Investments		 - - 0.00 113 139
Note & Lease Receivable		 - - - - 0.00
Accounts Receivable		 0.00 0.00 0.84 0.58 0.70
Prepaid Expenses		 0.09 0.72 0.95 1.35 1.15
Plant, Property, & Equipment, net		 0.09 0.54 0.49 0.44 0.34
Total Noncurrent Assets		 0.82 0.93 4.21 4.62 286
Intangible Assets		 - - 0.00 0.03 0.02
Other Noncurrent Operating Assets		 0.01 0.93 4.21 4.58 286
Total Liabilities & Shareholders' Equity		 18 44 95 152 781
Total Liabilities		 1.64 2.77 4.21 6.31 10
Total Current Liabilities		 1.64 2.10 3.63 6.05 9.88
Accrued Expenses		 1.56 1.91 3.33 5.76 9.64
Other Current Liabilities		 0.00 0.20 0.31 0.29 0.25
Total Noncurrent Liabilities		 0.00 0.67 0.58 0.26 0.19
Other Noncurrent Operating Liabilities		 0.00 0.67 0.58 0.26 0.19
Total Equity & Noncontrolling Interests		 -15 42 90 146 770
Total Preferred & Common Equity		 -15 42 90 146 770
Total Common Equity		 -15 42 90 146 770
Common Stock		 12 82 162 254 956
Retained Earnings		 -27 -40 -72 -108 -185
Accumulated Other Comprehensive Income / (Loss)		 -0.20 -0.39 -0.37 -0.66 -0.54

Quarterly Balance Sheets for Belite Bio

No quarterly balance sheets for Belite Bio are available.

Annual Metrics And Ratios for Belite Bio

This table displays calculated financial ratios and metrics derived from Belite Bio's official financial filings.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 - - - - - 39,339,960.00
DEI Adjusted Shares Outstanding		 - - - - - 39,339,960.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - -1.97
Growth Metrics		 - - - - - -
Profitability Metrics		 - - - - - -
Net Operating Profit after Tax (NOPAT)		 -4.02 -6.86 -8.97 -22 -28 -59
Return On Investment Capital (ROIC_SIMPLE)		 - - -21.63% -24.51% -19.20% -7.65%
Earnings before Interest and Taxes (EBIT)		 -5.74 -9.67 -13 -32 -40 -84
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -5.73 -9.64 -12 -31 -39 -84
Valuation Ratios		 - - - - - -
Leverage & Solvency		 - - - - - -
Liquidity Ratios		 - - - - - -
Cash Flow Metrics		 - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -5.41 -9.83 -25 -26 -336
Efficiency Ratios		 - - - - - -
Capital & Investment Metrics		 - - - - - -
Invested Capital		 0.00 -1.45 -0.59 2.27 0.67 278
Increase / (Decrease) in Invested Capital		 0.00 -1.45 0.86 2.86 -1.60 277
Book Value per Share		 $0.00 ($1.58) $2.08 $3.63 $5.00 $24.21
Tangible Book Value per Share		 $0.00 ($1.58) $2.08 $3.63 $5.00 $24.21
Total Capital		 0.00 17 42 90 146 770
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 0.00 -17 -42 -88 -145 -492
Capital Expenditures (CapEx)		 0.00 0.06 0.39 0.06 0.12 0.07
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 -1.55 -1.39 -1.85 -4.13 -8.03
Debt-free Net Working Capital (DFNWC)		 0.00 16 41 86 141 484
Net Working Capital (NWC)		 0.00 16 41 86 141 484
Net Nonoperating Expense (NNE)		 1.73 2.81 3.67 9.46 8.15 19
Net Nonoperating Obligations (NNO)		 0.00 -18 -42 -88 -145 -492
Total Depreciation and Amortization (D&A)		 0.02 0.03 0.20 0.40 0.45 0.18
Earnings Adjustments		 - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 ($0.63) ($1.19) ($1.18) ($2.31)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 19.98M 26.59M 30.54M 33.54M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 ($0.63) ($1.19) ($1.18) ($2.31)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 19.98M 26.59M 30.54M 33.54M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 24.90M 29.15M 31.83M 39.34M
Normalized Net Operating Profit after Tax (NOPAT)		 -4.02 -6.86 -8.97 -22 -28 -59
Debt Service Ratios		 - - - - - -
Payout Ratios		 - - - - - -

Quarterly Metrics And Ratios for Belite Bio

No quarterly metrics and ratios for Belite Bio are available.


Financials Breakdown Chart

Belite Bio Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Belite Bio's financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Belite Bio's net income appears to be on an upward trend, with a most recent value of -$77.61 million in 2025, rising from -$5.75 million in 2020. The previous period was -$36.14 million in 2024. View Belite Bio's forecast to see where analysts expect Belite Bio to go next.

Belite Bio's total operating income in 2025 was -$84.21 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $84.21 million

Over the last 5 years, Belite Bio's total revenue changed from $0.00 in 2020 to $0.00 in 2025, a change of 0.0%.

Belite Bio's total liabilities were at $10.07 million at the end of 2025, a 59.6% increase from 2024, and a 515.9% increase since 2021.

In the past 4 years, Belite Bio's cash and equivalents has ranged from $17.34 million in 2021 to $352.93 million in 2025, and is currently $352.93 million as of their latest financial filing in 2025.

Over the last 5 years, Belite Bio's book value per share changed from 0.00 in 2020 to 24.21 in 2025, a change of 2,420.9%.


Related Companies

Financial statements for NASDAQ:BLTE last updated on 4/3/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
ZENA Surges: 558% Revenue Growth Fuels Breakout Small-Cap Narrative!
ZenaTech (NASDAQ: ZENA) reported $12.9 million in full-year 2025 revenue, representing 558% year-over-year gro...
Equiscreen | Sponsoredtc pixel
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel
From the man who predicted 2008 crash…
Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...
Porter & Company | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
Memorial Day Sale! 85% Off Disruptors and Dominators!
Nvidia's Jensen Huang has laid out a plan for the world's first trillion-dollar robot - and one virtually unkn...
Weiss Ratings | Sponsoredtc pixel
SpaceX will mint billionaires. You won't be one of them.
By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...
Behind the Markets | Sponsoredtc pixel
SpaceX just filed. The clock is ticking.
Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...
The Oxford Club | Sponsoredtc pixel